Clinical value of circulating endothelial cells and of soluble CD146 levels in patients undergoing surgery for non-small cell lung cancer

M Ilie¹,², E Long¹,², V Hofman¹,²,³, E Selva³, C Bonnetaud³, J Boyer², N Vénissac¹,⁴, C Sanfiorenzo¹,⁵, B Ferrua⁶, C-H Marquette¹,⁵, J Mouroux¹,⁴ and P Hofman *,¹,²,³

¹IRCAN Inserm/CNRS Team 3, CLCC Centre Antoine Lacassagne, University of Nice Sophia Antipolis, Nice, France; ²Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, Nice, France; ³Tumor Biobank, Pasteur Hospital, Nice, France; ⁴Department of Thoracic Surgery, Pasteur Hospital, Nice, France; ⁵Department of Pneumology, Pasteur Hospital, Nice, France and ⁶Inserm C3M, Archet II Hospital, Nice, France

Background: Previous studies indicate that endothelial injury, as demonstrated by the presence of circulating endothelial cells (CECs), may predict clinical outcome in cancer patients. In addition, soluble CD146 (sCD146) may reflect activation of angiogenesis. However, no study has investigated their combined clinical value in patients undergoing resection for non-small cell lung cancer (NSCLC).

Methods: Data were collected from preoperative blood samples from 74 patients who underwent resection for NSCLC. Circulating endothelial cells were defined, using the CellSearch Assay, as CD146⁺ CD105⁺ CD45⁻ DAPI⁺. In parallel, sCD146 was quantified using an ELISA immunoassay. These experiments were also performed on a group of 20 patients with small-cell lung cancer, 60 healthy individuals and 23 patients with chronic obstructive pulmonary disease.

Results: The CEC count and the plasma level of sCD146 were significantly higher in NSCLC patients than in the sub-groups of controls (P<0.001). Moreover, an increased CEC count was associated with higher levels of sCD146 (P = 0.010). Both high CEC count and high sCD146 plasma level at baseline significantly correlated with shorter progression-free survival (P<0.001, respectively) and overall survival (P = 0.005; P = 0.009) of NSCLC patients.

Conclusions: The present study provides supportive evidence to show that both a high CEC count and a high sCD146 level at baseline correlate with poor prognosis and may be useful for the prediction of clinical outcome in patients undergoing surgery for NSCLC.

Despite the different therapeutic strategies developed to date, patients with non-small cell lung cancer (NSCLC) have a poor outcome. The 5-year overall survival (OS) of these patients is ~20–25% across all stages (Mountain, 2000; van Rens et al, 2000; Naruke et al, 2001; Goya et al, 2005; Blanchon et al, 2006; Pfannschmidt et al, 2007).

Metastasis is the primary cause of mortality in cancer patients (Siegel et al, 2013). In addition to the lack of effective treatment options, the absence of useful clinical indicators predicting prognosis and/or response to treatment may contribute to the poor prognosis of these patients. Tumour growth and metastasis depend on neovascularisation (Narazaki and Tosato, 2006;
Circulating endothelial cells (CECs) are mature viable cells that are shed from the endothelium, circulate within the bloodstream and still exhibit proliferative capacity despite their terminal differentiation (Beerepoot et al., 2004). Recent studies demonstrated that CECs have an important role in tumour neovascularisation either at the primary or the metastatic site (Furstenberger et al., 2006; Goon et al., 2006; Narazaki and Tosato, 2006; Weis and Cheresh, 2011). The number of CECs and the extent of vascular damage are increased in a variety of vascular disorders including cardiovascular diseases, vasculitis and infectious diseases (Mutin et al., 1999; Mutunga et al., 2001; Woywodt et al., 2003; Beerepoot et al., 2004). It is noteworthy that the CEC count is increased in cancer patients compared with healthy subjects and may correlate with tumour progression (Mancuso et al., 2001; Beerepoot et al., 2004; Rowand et al., 2007). Moreover, the CEC count in cancer patients significantly decreased after surgical removal of the tumour and/or treatment with chemotherapy of the patient (Mancuso et al., 2001; Kawashii et al., 2009). In addition, CEC kinetics and viability are promising predictors of the response to treatment with anti-angiogenic agents in patients with advanced breast cancer or colorectal cancer (Mancuso et al., 2006; Malka et al., 2012). Besides monitoring the anti-tumour activity, a marker such as CEC would reveal tumour growth and disease progression at an early stage in view of the known fragility of the tumour vasculature compared with the healthy vasculature (Strijbos et al., 2008). However, because of the technical difficulties and challenges associated with CEC measurement, data regarding the significance of CECs in patients with early-stage cancer are still lacking. An approach using an automated rare cell detection system has proven to be highly accurate and reliable in enumeration and isolation of CECs from peripheral blood (Rowand et al., 2007). However, very few studies to date have evaluated the clinical value of CECs in NSCLC patients using this methodology (Kawashii et al., 2009).

In addition to the number of CECs in the blood, other biomarkers are thought to reflect the presence of angiogenesis and/or vascular endothelial alteration, such as the concentration of soluble factors including soluble CD146 (sCD146) in the blood. CD146 (also referred to as MUC18, MCAM, Mel-CAM, S-Endo-1 and P1H12 antigen) is a transmembrane glycoprotein that is constitutively expressed in the human endothelium, irrespectively of the anatomical localisation (Lehmann et al., 1989; Bardin et al., 1998; Bardin et al., 2003). CD146 is localised at the intercellular boundaries of endothelial cells and is involved in the control of cell cohesion (Bardin et al., 1996a; Shih, 1999; Bardin et al., 2001). Moreover, CD146 may have a key role in endothelial cell activity and angiogenesis (Kang et al., 2006). In addition to the membrane-anchored form of CD146, a soluble form of CD146 (sCD146) has been identified using an ELISA assay in the supernatant of cultured human endothelial cells and in the plasma of healthy subjects (Bardin et al., 1998; Bardin et al., 2003; Furstenberger et al., 2005). The plasma concentration of sCD146 is modulated in inflammatory diseases associated with endothelial alterations (Bardin et al., 2006). However, there is no current data concerning the level of sCD146 in lung cancer patients.

In this setting, we hypothesised that CEC detachment from the vascular wall may be associated with the release of sCD146. The purpose of this study was: (1) to quantify CEC levels in patients undergoing surgery for NSCLC, (2) to quantify the plasma level of sCD146 in the same cohort of patients, (3) to compare the absolute number of CECs and the level of sCD146 in these patients, and, finally, (4) to correlate the results with different clinicopathological parameters and the outcome of patients.

Patients

Seventy-four patients who underwent surgery for NSCLC (including seven patients with neoadjuvant chemotherapy) between January 2009 and January 2011 at the Pasteur Hospital (Department of Thoracic Surgery, University of Nice Sophia Antipolis, France) were included in this study. In addition, 20 patients with histologically and/or cytopathologically confirmed chemotherapy-naive small-cell lung cancer (SCLC) were enrolled in the study to test for the specificity of candidate biomarkers. Two control populations were included in the study: 20 patients with chronic obstructive pulmonary disease (COPD) (16 males, 4 females; mean age 68 years, range 55–77 years; all smokers), as well as 42 age, sex and smoking status-matched healthy individuals (28 males, 14 females; mean age 57 years, range 21–74; 35 current smokers). After approval by the local Ethics Committees (Nice University Hospital Centre), written informed consent was obtained from participants after explaining the nature of the study and the study was performed according to the guidelines of the Declaration of Helsinki. Criteria for patient inclusion in the study were: NSCLC histology performed according to WHO criteria and the latest recommendations of the international association for the study of lung cancer (Travis et al., 2004, 2011), tumour stage I to IV (7th edition of UICC-TNM staging system, AJCC) (Goldstraw, 2009), patients treated with surgery of the primary tumour (wedge resection, lobectomy or pneumonectomy), availability of clinicopathological and outcome data, and no transbronchial and/or transparietal chest biopsies at least 15 days before surgery. The main clinical and pathological data are summarised in Table 1. In SCLC patients, blood samples were collected for analysis within 7 days before commencing treatment (baseline) chemotherapy cycle.

Methods

CellSearch technology (Veridex LLC, Raritan, NJ, USA) was carried out using previously described protocols (Strijbos et al., 2008; Malka et al., 2012). Briefly, 4 ml of peripheral blood was taken before anaesthesia and collected in the CellSave preservative tubes (Veridex LLC). The first 2 ml of peripheral blood was discarded to avoid contamination with endothelial cells from peripheral venules. Samples were maintained at room temperature and processed within 24 h after collection. The CellTracks AutoPrep System (Veridex LLC), the CellSearch Endothelial Cell Kit (Veridex LLC) and the CellSpotter Analyzer System (Veridex LLC) were used to enumerate the CECs. The CellSearch Endothelial Cell Kit was used for immunomagnetic enrichment using ferrofluids coupled to an anti-CD146 antibody. After enrichment, the following reagents were added: the nuclear dye 4,6-diamidino-2-phenylindole (DAPI), and fluorochrome-conjugated monoclonal antibodies: phycoerythrin-conjugated CD105, and allopocyanocyan-conjugated CD45, a pan-leukocyte antigen was included to exclude haematopoietic cells from analysis. Analysis was done using image cytometry, in which CECs were defined as having an oval to elongated undamaged morphology and were CD146 + DAPI + CD105 + CD45– (Supplementary Figure 1) (Rowand et al., 2007; Strijbos et al., 2008). The CEC count was expressed as the number of positive cells per 1 ml of blood. Reproducibility was tested by performing two replicates of 20 different samples (Supplementary Figure 2).

In parallel, peripheral blood was drawn into EDTA tubes (Becton Dickinson, Le Pont-De-Claix, France). Within 1 h, the tubes were subjected to centrifugation at 820 g for 10 min. Transferred 1-ml aliquots of the plasma to 1.5-ml tubes was done followed by centrifugation at 16 000 g for 10 min to pellet any remaining cellular debris. The supernatant was transferred to fresh tubes and stored at −80 °C until use.

Soluble CD146 levels were determined with a commercial enzyme-linked immunosorbent assay (CY-QUANT ELISA, www.bjcancer.com | DOI:10.1038/bjc.2014.11
Table 1. Clinical and pathological variables of the 53 patients with operable non-small cell lung carcinoma enrolled in the study

| Variables                        | Overall n (%) | Low     | High    | P-value | Low     | High    | P-value |
|----------------------------------|---------------|---------|---------|---------|---------|---------|---------|
| **CEC count (per ml)**           |               |         |         |         |         |         |         |
| **sCD146 levels (ng ml⁻¹)**      |               |         |         |         |         |         |         |
| **Age (years)ᵃ**                 |               |         |         |         |         |         |         |
| Mean ± s.d.                      | 65.2 ± 8.6    | 65.4 ± 8.2 | 65 ± 9 | 0.710  | 63.9 ± 9.1 | 66.5 ± 8 | 0.205  |
| **Genderᵇ**                      |               |         |         |         |         |         |         |
| Male                             | 54 (73%)      | 24 (44%) | 30 (56%) | 0.585  | 25 (46%) | 29 (54%) | 0.216  |
| Female                           | 20 (27%)      | 9 (45%)  | 11 (55%) |         | 12 (60%) | 8 (40%)  |         |
| **ECOG PS**                      |               |         |         |         |         |         |         |
| 0                                | 44 (59%)      | 24 (55%) | 20 (45%) | 0.451  | 26 (59%) | 18 (41%) | 0.937  |
| 1                                | 30 (41%)      | 19 (63%) | 11 (27%) |         | 18 (60%) | 12 (40%) |         |
| **Baseline FEV₁**                |               |         |         |         |         |         |         |
| < 2 L                            | 35 (47%)      | 23 (66%) | 12 (24%) | 0.931  | 25 (71%) | 10 (29%) | 0.262  |
| ≥ 2 L                            | 39 (53%)      | 26 (67%) | 13 (23%) |         | 23 (59%) | 16 (41%) |         |
| **Hb level (g dl⁻¹)**            |               |         |         |         |         |         |         |
| < 12                             | 27 (37%)      | 18 (67%) | 9 (23%)  | 0.900  | 16 (59%) | 11 (41%) | 0.173  |
| ≥ 12                             | 47 (63%)      | 32 (68%) | 15 (22%) |         | 35 (74%) | 12 (26%) |         |
| **Smoking historyᵇ**             |               |         |         |         |         |         |         |
| Never                            | 9 (12%)       | 3 (33%)  | 6 (67%)  | 0.361  | 4 (44%)  | 5 (56%)  | 0.500  |
| Current and former               | 65 (88%)      | 30 (46%) | 35 (54%) |         | 33 (51%) | 32 (49%) |         |
| **Neoadjuvant chemotherapy**     |               |         |         |         |         |         |         |
| No                               | 67 (91%)      | 36 (54%) | 31 (46%) | 0.370  | 38 (57%) | 29 (43%) | 0.982  |
| Yes                              | 7 (9%)        | 5 (71%)  | 2 (29%)  |         | 4 (57%)  | 3 (23%)  |         |
| **Tumour sizeᵃ**                 |               |         |         |         |         |         |         |
| Mean ± s.d.                      | 3.8 ± 2       | 3.5 ± 2.3 | 4.1 ± 1.8 | 0.226  | 3.5 ± 1.8 | 3.9 ± 2.1 | 0.544  |
| **Histological subtypesᵇ**       |               |         |         |         |         |         |         |
| Adenocarcinoma                   | 50 (68%)      | 23 (46%) | 27 (54%) | 0.461  | 25 (50%) | 25 (50%) | 0.598  |
| Squamous cell carcinoma          | 24 (32%)      | 10 (42%) | 14 (58%) |         | 12 (50%) | 12 (50%) |         |
| **Histological gradeᵇ**          |               |         |         |         |         |         |         |
| Well                             | 32 (43%)      | 16 (50%) | 16 (50%) | 0.441  | 14 (44%) | 18 (56%) | 0.636  |
| Moderate                         | 26 (35%)      | 9 (35%)  | 17 (65%) |         | 14 (54%) | 12 (46%) |         |
| Poor                             | 16 (22%)      | 8 (50%)  | 8 (50%)  |         | 9 (56%)  | 7 (44%)  |         |
| **pTNM stageᵇ**                  |               |         |         |         |         |         |         |
| I                                | 25 (34%)      | 12 (48%) | 13 (52%) | 0.342  | 15 (60%) | 10 (40%) | 0.129  |
| II                               | 32 (43%)      | 16 (50%) | 16 (50%) |         | 17 (53%) | 15 (47%) |         |
| III + IV                         | 17 (23%)      | 5 (29%)  | 12 (71%) |         | 5 (29%)  | 12 (71%) |         |

Abbreviations: CEC = circulating endothelial cells; ECOG = Eastern Cooperative Oncology Group; FEV₁ = forced expiratory volume in one second; PS = performance status; TNM = tumour-node-metastasis. The baseline CEC count, sCD146 level according to the patient characteristics are shown.

ᵃT-test.    ᵇw²-test.
predictors of survival. Variables that were associated with survival with a P-value < 0.20 in the univariate analysis were included in the multivariate regression. Differences were considered significant when a P-value was < 0.05. All statistical evaluations were performed using SPSS for Windows software system, version 16.0.0 (SPSS, Chicago, IL, USA).

RESULTS

The baseline CEC count, the sCD146 level and correlation with clinicopathological parameters of patients. The detection and enumeration of CECs in the current cohort demonstrated a significantly higher baseline CEC count in the blood of NSCLC patients (median 114 CEC per ml; range, 22–661 per ml) than in SCLC patients (median 46 CEC per ml; range, 26–94 per ml), COPD patients (median 22 CEC per ml; range, 7–37 per ml) or in healthy controls (median 3 CEC per ml; range, 1–13 per ml) (P < 0.001, Figure 1). Higher CEC count was observed in SCLC patients when compared with COPD patients or the healthy individuals (Figure 1). There was a tendency towards higher CEC count in COPD patients when compared with healthy subjects (Figure 1). There was a tendency towards higher CEC count in COPD patients when compared with healthy subjects (P = 0.068). No significant difference was observed in the control group according to gender, age and tobacco status (data not shown).

Baseline sCD146 levels were significantly higher in NSCLC patients (median 275 ng ml⁻¹, range, 89–905.4 ng ml⁻¹) as compared with SCLC patients (median 133.5 ng ml⁻¹, range, 66–193 ng ml⁻¹), COPD patients (median 107 ng ml⁻¹, range, 60–180 ng ml⁻¹) and healthy subjects (median 78 ng ml⁻¹, range, 20–349 ng ml⁻¹) (P < 0.001, Figure 1). Significant variations were observed between SCLC patients and COPD patients or healthy individuals (Figure 1). No significant difference was observed in the control group according to gender, age and tobacco status (data not shown).

A significant positive correlation was observed between the CEC count and sCD146 levels in NSCLC patients (r = 0.9, P = 0.010; Figure 2). Correlation of the coefficient values for variation of duplicate CEGs and sCD146 samples from the same subject were R² = 0.90 and 0.92, respectively.

Furthermore, we categorised the CEC count per ml and sCD146 levels as ‘low’ and ‘high’ using the 75th percentile of the interquartile range of the median value as the cutoff, as previously described (Malka et al., 2012). Accordingly, the range of low sCD146 levels was between 89 and 219.1 ng ml⁻¹, and the range of high sCD146 levels was between 220.7 and 905.4 ng ml⁻¹.

Among the NSCLC patients, there was no significant difference in the CEC count and sCD146 level according to age, gender, performance status, FEV₁, Hb level, smoking history, tumour size, histological subtypes, tumour grade or pTNM stage (P > 0.05, Table 1).

The CEC count, sCD146 levels and clinical outcome. At the last follow-up, 30 out of 74 (41%) patients had local (55%), regional (27%) or distant (18%) tumour recurrence and 22 out of 74 (30%) patients died specifically from cancer progression.

The mean PFS was 36.9 months (95% CI, 32.6–41.3). In the univariate analysis, the clinical factor that significantly associated with PFS was the pTNM stage (P = 0.012). The unadjusted survival analysis showed that patients with a high baseline CEC count and a high sCD146 level had poor PFS (P < 0.001, P < 0.001, respectively; Figure 3A and B) and worse OS (P = 0.005, P = 0.009, respectively; Figure 3D and E). This significance was even higher when adjusted for both endothelial biomarkers (P < 0.001, respectively; Figure 3C and F). Patients with only one increased endothelial marker harboured intermediate outcomes.

The risk of progression was higher for patients with stage III + IV (P = 0.030), high CEC count (P = 0.001) and high sCD146 plasma level (P = 0.002; Table 2). The multivariate Cox analysis revealed that the pTNM stage (P = 0.086), the CEC count (P = 0.006) and sCD146 level (P = 0.020) were the prognostic factors that influence the OS of NSCLC patients (Table 2).

DISCUSSION

This study demonstrated that the baseline CEC count was markedly higher for NSCLC patients than for healthy individuals.

![Figure 1](https://www.bjcancer.com/images/figure1.png)  
**Figure 1.** Distribution of the absolute CEC count per ml (left) and the sCD146 level (ng ml⁻¹) (right) in 74 patients with operable NSCLC, 20 patients with SCLC and in controls (60 healthy individuals and 23 patients with COPD). The Mann–Whitney U-test was used for testing the significance.

![Figure 2](https://www.bjcancer.com/images/figure2.png)  
**Figure 2.** Correlation between the CEC count and the plasma level of sCD146 in 74 patients with operable NSCLC.
documented in many human diseases, including different types of cancers. In cancer patients, the level of CECs is persistently higher over time than that of healthy individuals, and this increased level has been identified as a surrogate marker of neovascularisation and anti-angiogenic drug activity (Goon et al., 2006; Mancuso et al., 2006; Malka et al., 2012). We also observed an increased number of CECs in SCLC patients compared with healthy individuals and COPD patients. The CEC count was significantly lower than in NSCLC patients. As our SCLC population was limited in size, the value of CEC in SCLC patients should be further evaluated in larger series. Most importantly, our results show that the CEC count is associated with clinical outcome in NSCLC patients undergoing surgery, and thus may be a prognostic factor for this disease. In our study, patients with a high CEC count at baseline had a significantly worse PFS and OS. A majority of reports showed that high baseline CEC levels above the 75th percentile significantly correlated with prognosis, and could be useful as prognostic markers in patients with advanced NSCLC (Fleitas et al., 2010; Morita et al., 2011; Wang et al., 2013). In contrast, a study of 31 patients with advanced NSCLC treated with first-line carboplatin and paclitaxel reported that a CEC count of > 400/4 ml at baseline showed a significantly improved PFS. However, no statistical data were presented in this study, which was limited in size and follow-up, to justify the choice of the cutoff (Kawaiishi et al., 2009).

Endothelial progenitor cells (EPCs), which are circulating cells that originate from bone marrow, have the ability to form endothelial colonies in vitro, and to contribute to neovascularisation (Mancuso et al., 2003; Strijbos et al., 2008). In theory, cEPCs may be a more appropriate surrogate of tumour vascularisation. Subsequently, the pre-treatment level of cEPCs was proposed as a promising candidate biomarker for disease progression and prediction of clinical outcome in NSCLC (Dome et al., 2006; Fleitas et al., 2010; Nowak et al., 2010; Roodhart et al., 2010; Vroling et al., 2010). However, the clinical evaluation of cEPCs has been hampered by the extreme rarity of these cells and the lack of
consensus on the surface marker phenotype and on the techniques used for cEPC enumeration (Peters et al, 2005; Wang et al, 2013).

Nevertheless, a decrease in both CECs and EPCs correlated with a longer PFS or OS in the majority of studies, before and after effective anti-angiogenic therapy and/or chemotherapy (Chu et al, 2012; Wang et al, 2013).

The present study showed that sCD146 levels were significantly higher in NSCLC patients than in healthy subjects. Previous studies have shown that sCD146 is detectable in the human blood and its level is modulated in different pathologies, such as inflammatory bowel diseases, vasculitis, pathologic pregnancies and chronic renal failure (Bardin et al, 2003; Pasquier et al, 2005; Bardin et al, 2006).

Furthermore, we showed a positive correlation between the CEC count and the sCD146 level, indicating that both biomarkers can be indirect surrogates of tumour vascularisation, as previously suggested for these individual markers (Monestiroli et al, 2001; Harhouri et al, 2010). For instance, sCD146 is involved in inflammation by specifically binding to monocytes and thereby stimulating transendothelial migration, as well as in angiogenesis (Bardin et al, 2009; Harhouri et al, 2010; Stalin et al, 2013). Thus, sCD146 exhibits chemotactic activity on different cell types involved in vessel formation, including endothelial cells. In addition, treatment of EPCs with sCD146 led to increased migration, proliferation and the capacity to form capillary-like structures. Finally, local treatment with sCD146 led to the recruitment of EPCs and to an increase in blood flow and neovessel formation (Harhouri et al, 2010). Interestingly, recent evidence suggested that sCD146, through inhibition of endothelial cell adhesion, may have a role in CEC migration and homing (Jiang et al, 2012; Wang and Yan, 2013). Moreover, the binding of CD146 to an anti-CD146 monoclonal antibody inhibited p38 mitogen-activated protein kinase phosphorylation, suppressed NF-kB activation and downregulated matrix metalloproteinase 9 and intercellular adhesion molecule 1 expression, suggesting that the CD146/NF-kB axis is critical in endothelial cell migration, angiogenesis and tumour metastasis (Ouhlít et al, 2009).

We further investigated whether sCD146 can assist in determining the outcome of NSCLC surgical patients at baseline. Our results support the hypothesis that CEC counts together with sCD146 levels are associated with clinical outcome in NSCLC patients undergoing surgery. We showed that patients with a high CEC count and an elevated sCD146 level at baseline had a significantly worse PFS and OS, whereas patients with a single high endothelial marker harboured intermediate outcomes, suggesting a possible synergistic effect on cancer progression.

CD146 is a member of the immunoglobulin superfamily that was originally identified as a melanoma marker and has a role in tumour metastasis (Shih, 1999). Recent data suggest that CD146 may be involved in tumour development and may influence tumour prognosis in a number of solid tumours (Liu et al, 2012; Zeng et al, 2012b; Kapoor, 2013). It is expressed in a high proportion of NSCLC and might be predictive of shortened patient survival in lung adenocarcinomas (Kristiansen et al, 2003; Oka et al, 2012). Moreover, CD146 promotes cancer progression by induction of epithelial–mesenchymal transition, a critical step in tumour metastasis, through modulating the remodelling of cytoskeleton (Luo et al, 2012; Zeng et al, 2012a).

In conclusion, our findings demonstrate that the CEC count and the sCD146 plasma level might be suitable biomarkers at baseline for predicting outcome of patients with NSCLC following surgical resection.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Bardin N, Anfoso F, Masse JM, Cramer E, Sabatier F, Leivic A, Sampol J, Dignat-George F (2001) Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 98(13): 3677–3684.

Bardin N, Blot-Chabaud M, Despoix N, Kebir A, Harhouri K, Arsanto JP, Espinoso L, Perrin P, Robert S, Vely F, Sabatier F, Leovic A, Kaplaniski G, Sampol J, Dignat-George F (2009) CD146 and its soluble form regulate monocyte transendothelial migration. Arterioscler Thromb Vasc Biol 29(5): 746–753.

Bardin N, Frances V, Combes V, Sampol J, Dignat-George F (1998) CD146: biosynthesis and production of a soluble form in human cultured endothelial cells. FEBS Lett 421(1): 12–14.

Bardin N, Frances V, Lesaule G, Horschowski N, George F, Sampol J (1996a) Identification of the S-Endo 1 endothelial-associated antigen. Biochem Biophys Res Commun 218(1): 210–216.

Bardin N, George F, Mutin M, Brisson C, Horschowski N, Frances V, Lesaule G, Sampol J (1996b) S-Endo 1, a pan-endothelial monoclonal antibody recognizing a novel human endothelial antigen. Tissue Antigens 48(5): 531–539.

Bardin N, Moal V, Anfoso F, Daniel L, Brunet P, Sampol J, Dignat George F (2003) Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. Thromb Haemost 90(5): 915–920.

Bardin N, Reumaux D, Geboes K, Colombel JF, Blot-Chabaud M, Sampol J, Duthilleul P, Dignat-George F (2006) Increased expression of CD146, a new marker of the endothelial junction in active inflammatory bowel disease. Inflamm Bowel Dis 12(1): 16–21.

Beerepoot LV, Mehra N, Vermaat J, Zonnenberg BA, Gebbink MF, Voest EE (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15(1): 139–145.

Blanchon F, Grivaux M, Asselain B, Lebas FX, Orlando JP, Piquet J, Zareik M (2006) 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol 7(10): 830–836.

Chu TQ, Ding H, Garfield DH, Gu AQ, Pei J, Du WD, Han BH (2012) Can determination of circulating endothelial cells and serum caspase-cleaved CK18 predict for response and survival in patients with advanced non-small-cell lung cancer receiving cetuximab and panitumumab therapy? A retrospective study. J Thorac Oncol 7(12): 1781–1789.

D’Souza-Schorey C, Clancy JW (2012) Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev 26(12): 1287–1299.

Dome B, Timar J, Dobos J, Meszaros L, Raso E, Paku S, Kenessy J, Ostoros G, Magyar M, Ladanyi A, Bogos K, Tovari J (2006) Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 66(14): 7341–7347.

Ebos JM, Kerbel RS (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8(4): 210–221.

Fleitas T, Martínez-Sales V, Gomez-Codina J, Martin M, Reyes G (2010) Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer. Clin Transl Oncol 12(8): 521–525.

Furstenberger G, von Moos R, Lucas R, Thurlimann B, Senn HJ, Hamacher J, Boneberg EM (2006) Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. Br J Cancer 94(4): 524–531.

Furstenberger G, von Moos R, Senn HJ, Boneberg EM (2005) Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis. Br J Cancer 93(7): 793–798.

Goldstraw P (2009) The 7th Edition of TNM in Lung Cancer: what now? J Thorac Oncol 4(6): 671–673.

Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD (2006) Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8(2): 79–88.

Goya T, Asamura H, Yoshimura H, Kato H, Shimokata K, Tsuchiya R, Sohara Y, Miya T, Miyaoa E (2005) Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50(2): 227–234.
Harhouri K, Kebir A, Guillet B, Foucault-Bertaud A, Voyerenko S, Pierrecchi-Marti MD, Berenguer C, Lamy E, Vely F, Pisano P, Ouakhi L, Sabatier F, Sampol J, Bardin N, Dignat-George F, Blot-Chabaud M (2010) Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood 115(18): 3843–3851.

Jiang T, Zhuang J, Duan H, Luo Y, Zeng Q, Fan K, Ye Z, Hao J, Feng J, Yang D, Yan X (2012) CD146 is a coreceptor for VEGFR-2 in tumor angiogenesis. Blood 120(11): 2330–2339.

Kang Y, Wang F, Feng J, Yang D, Yang X, Yan X (2006) Knockdown of CD146 reduces the migration and proliferation of human endothelial cells. Cell Res 16(3): 313–318.

Kapoor S (2013) CD146 expression and its close relationship to tumor suppression in systemic malignancies suggest bad gall bladder carcinomas. Tumour Biol 34(2): 1273–1274.

Kawaiishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Watabe T, Shimoda Y, Aroa T, Nishio K, Tamura T, Koizumi F (2009) Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 4(2): 208–213.

Kristiansen G, Yu Y, Schluns K, Sers C, Dietel M, Petersen I (2003) Expression of the cell adhesion molecule CD146/MCAM in non-small cell lung cancer. Anal Cell Pathol 25(2): 77–81.

Lehmenn JM, Riethmuller G, Johnson JP (1989) MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. Proc Natl Acad Sci USA 86(24): 9891–9895.

Liu WF, Ji SR, Sun JJ, Zhang Y, Liu ZY, Liang AB, Zeng HZ (2012) CD146 expression correlates with epithelial-mesenchymal transition markers and a poor prognosis in gastric cancer. Int J Mol Sci 13(5): 6399–6406.

Luo Y, Zheng C, Zhang J, Lu D, Zhuang X, Seng F, Jeng Y, Yang D, Yan X (2012) Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration. Oncogene 31(3): 306–321.

Malka D, Boige V, Jacques N, Mutin M, Canavy I, Blann A, Bory M, Sampol J, Dignat-George F (1999) Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 5(3): 261–262.

Mountain CF (2000) The international system for staging lung cancer. J Thorac Oncol 5(4): 106–115.

Mutua G, Murphy B, Blann A, Bory M, Sampol J, Dignat-George F (1999) Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 93(9): 2951–2958.

Mizuno M, Nambu Y, Miura Y, Hidaka H, Inoue K, Hasegawa K, Sato K, Nakano M, Miura T, Miyazaki T, Matsubayashi J, Miyamoto M, Sano M, Watanabe H, Shirakawa Y, Ito T, Ito H (2011) Endothelial progenitor cells are associated with response to chemotherapy in human non-small cell lung cancer. J Cancer Res Clin Oncol 137(12): 1849–1857.

Mountain CF (2005) The international system for staging lung cancer. Semin Oncol Surg 18(2): 106–115.

Muir T, Cavanagh I, Blann A, Bory M, Sampol J, Dignat-George F (1999) Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 93(9): 2951–2958.

Mizuno M, Nambu Y, Miura Y, Hidaka H, Inoue K, Hasegawa K, Sato K, Watanabe H, Shirakawa Y, Ito T, Ito H (2011) Endothelial progenitor cells are associated with response to chemotherapy in human non-small cell lung cancer. J Cancer Res Clin Oncol 137(12): 1849–1857.

Mountain CF (2005) The international system for staging lung cancer. Semin Oncol Surg 18(2): 106–115.

Muir T, Cavanagh I, Blann A, Bory M, Sampol J, Dignat-George F (1999) Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 93(9): 2951–2958.

Mizuno M, Nambu Y, Miura Y, Hidaka H, Inoue K, Hasegawa K, Sato K, Watanabe H, Shirakawa Y, Ito T, Ito H (2011) Endothelial progenitor cells are associated with response to chemotherapy in human non-small cell lung cancer. J Cancer Res Clin Oncol 137(12): 1849–1857.

Mountain CF (2005) The international system for staging lung cancer. Semin Oncol Surg 18(2): 106–115.

Muir T, Cavanagh I, Blann A, Bory M, Sampol J, Dignat-George F (1999) Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood 93(9): 2951–2958.
Wang Z, Yan X (2013) CD146, a multi-functional molecule beyond adhesion. Cancer Lett 330(2): 150–162.

Weis SM, Cheresh DA (2011) Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med 17(11): 1359–1370.

Woywodt A, Streiber F, de Groot K, Regelsberger H, Haller H, Haubitz M (2003) Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 361(9353): 206–210.

Yoneda K, Tanaka F, Kondo N, Orui H, Hashimoto M, Takuwa T, Matsumoto S, Okumura Y, Tsubota N, Sato A, Tsujimura T, Kuribayashi K, Pukuoka K, Nakano T, Hasegawa S (2012) Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM). Ann Surg Oncol 19(13): 4229–4237.

Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, Feng J, Yang D, Fu L, Yan X (2012b) CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci USA 109(4): 1127–1132.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)